Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: placebo
Drug: telmisartan + HCTZ
Drug: amlodipine

First Posted Date: 2013-07-30

Last Posted Date: 2016-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 132

Registration Number: NCT01911780

Locations: 🇯🇵
1348.2.021 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵
1348.2.019 Boehringer Ingelheim Investigational Site, Kita-ku, Osaka-shi, Osaka, Japan
🇯🇵
1348.2.001 Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan

and more 14 locations

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Phase 1

Completed

Conditions: Liver Cirrhosis
Hepatitis C

Interventions: Drug: BI 201335

First Posted Date: 2013-07-29

Last Posted Date: 2015-08-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2

Registration Number: NCT01909778

Locations: 🇩🇪
1220.15.49006 Boehringer Ingelheim Investigational Site, Mainz, Germany

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773

First Posted Date: 2013-07-24

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01907113

Locations: 🇩🇪
1245.12.1 Boehringer Ingelheim Investigational Site, Kiel, Germany
🇩🇪
1245.12.2 Boehringer Ingelheim Investigational Site, Neuss, Germany

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2

Terminated

Conditions: Mesothelioma

Interventions: Drug: Pemetrexed
Drug: Nintedanib
Drug: Cisplatin
Drug: Placebo

First Posted Date: 2013-07-24

Last Posted Date: 2019-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 545

Registration Number: NCT01907100

Locations: 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇺🇸
Texas Oncology - McAllen, McAllen, Texas, United States
🇺🇸
Cancer Care Northwest Centers, PS, Spokane Valley, Washington, United States

and more 119 locations

A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 853520

First Posted Date: 2013-07-23

Last Posted Date: 2014-09-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT01905111

Locations: 🇨🇳
1300.15.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
🇯🇵
1300.15.81001 Boehringer Ingelheim Investigational Site, Kashiwa-shi, Chiba, Japan

PMS of Trazenta on the Long-term Use as Add-on Therapy

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Trazenta

First Posted Date: 2013-07-22

Last Posted Date: 2019-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4057

Registration Number: NCT01904383

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Trajenta duo

First Posted Date: 2013-07-19

Last Posted Date: 2018-12-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 724

Registration Number: NCT01903356

Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 144807 intermediate dose
Drug: BI 144807 high dose

First Posted Date: 2013-07-12

Last Posted Date: 2013-09-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT01897597

Locations: 🇩🇪
1313.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin

First Posted Date: 2013-07-12

Last Posted Date: 2019-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6991

Registration Number: NCT01897532

Locations: 🇺🇸
DM Clinical Research, Tomball, Texas, United States
🇺🇸
Pioneer Research Solutions, Inc., Sugar Land, Texas, United States
🇦🇷
Prevencion Cardiovascular Salta, Salta, Salta, Argentina

and more 633 locations

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Pradaxa, dabigatran etexilate

First Posted Date: 2013-07-11

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT01896297

Locations: 🇺🇸
1160.173.026 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸
1160.173.011 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States
🇺🇸
1160.173.019 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy